- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06510582
Tratamiento del hematoma subdural crónico con inyección intraarterial de bevacizumab (CHAI)
Tratamiento del hematoma subdural crónico con inyección intraarterial de Avastin® (bevacizumab): ensayo clínico de fase 1/2, abierto y no aleatorizado
The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH).
The main questions it aims to answer are:
- Is bevacizumab infusion safe in cSDH patients?
- Is bevacizumab infusion effective in treating cSDH?
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This protocol was originally proposed as a phase I/II trial. Phase 1 was completed; planned phase 2 was discontinued prior to initiation.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Cooper University Health Care
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Adult patients (≥18 years)
-
Radiographic evidence of chronic subdural hematoma, including
- Persistence of subdural blood more than 10 days after index traumatic injury or event
- Presence of mixed density blood
- Presence of subdural membranes
-
Can obtain informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.
Exclusion Criteria:
- Pregnant, breastfeeding, or unwilling to practice contraception during participation in the study.
- Patients with concomitant intracranial pathology other than subdural hematoma (e.g., intracranial malignancy).
- Patients with known hypersensitivity to bevacizumab.
- Patients with radiographic evidence of mass effect.
- Patients have focal neurological deficits attributed to subdural hematoma.
- Patient had craniotomy or burr hole operative procedures performed in preceding two weeks prior to onset of subdural hematoma.
- Secondary causes apart from trauma for the chronic subdural hematoma, such as underlying vascular abnormality or tumor.
- Emergent surgical evacuation is required for the patient.
- Non-convexity chronic subdural hematoma, as the middle meningeal artery will not supply this area.
- Coagulation abnormalities, including platelet count <100,000 and/or international normalized ratio of <1.5 despite attempts for correction.
- Patients with known contraindications for angiography. Patients with contrast allergy will be premedicated with diphenhydramine and steroids.
- Patient has known active systemic infection or sepsis.
- Patient has contradiction to anesthetic agents used for conscious sedation/monitored anesthesia care (MAC).
- Patient has life expectancy of less than six months due to comorbid terminal conditions.
- Patient has a premorbid modified Rankin score (mRS) of 5 or greater.
- Concurrent participation in another research protocol for investigation of an experimental therapy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Phase 1 Unilateral cSDH/ 2mg/kg Arm
During phase 1, single 2mg/kg dose of bevacizumab to treat unilateral cSDH |
Single 2mg/kg dose of bevacizumab to treat unilateral cSDH |
|
Experimental: Phase 1 Bilateral cSDH/ 4mg/kg Arm
During phase 1, two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH |
Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants with Serious Adverse Events
Periodo de tiempo: Up to 3 months after study treatment
|
Reported serious adverse events classified using MedDRA and CTCAE, in addition to treatment-related events and all other adverse events |
Up to 3 months after study treatment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate of Hematoma Recurrence
Periodo de tiempo: 3 months after study treatment and 6 months after study treatment
|
Rate of hematoma recurrence or progression requiring intervention and/or readmission |
3 months after study treatment and 6 months after study treatment
|
|
Rate of Complete Hematoma Resolution
Periodo de tiempo: 3 months after study treatment and 6 months after study treatment
|
Rate of complete hematoma resolution compared to baseline on imaging |
3 months after study treatment and 6 months after study treatment
|
|
Rate of Partial Hematoma Resolution
Periodo de tiempo: 3 months after study treatment and 6 months after study treatment
|
Rate of at least 50% or greater reduction in hematoma size from baseline on imaging |
3 months after study treatment and 6 months after study treatment
|
|
Change in Hematoma Size
Periodo de tiempo: 3 months after study treatment and 6 months after study treatment
|
Change in hematoma size measured in millimeters on imaging |
3 months after study treatment and 6 months after study treatment
|
|
Change in Clinical Neurological Symptom Scale Scores: NIHSS
Periodo de tiempo: 3 months after study treatment and 6 months after study treatment
|
Change in National Institutes of Health Stroke Scale (NIHSS) scores, scores range from 0 to 42, with higher scores indicating more severe neurological deficit |
3 months after study treatment and 6 months after study treatment
|
|
Change in Clinical Neurological Symptom Scale Scores: GCS
Periodo de tiempo: 3 months after study treatment and 6 months after study treatment
|
Change in Glasgow Coma Scale (GCS) scores, ranging from 3 to 15 with lower score indicating more impaired consciousness |
3 months after study treatment and 6 months after study treatment
|
|
Change in Clinical Neurological Symptom Scale Scores: mRS
Periodo de tiempo: 3 months after study treatment and 6 months after study treatment
|
Change in modified Rankin Scale (mRS) scores, ranges from 0-6 with higher score indicating worse functional outcome |
3 months after study treatment and 6 months after study treatment
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants with Anatomical Variants
Periodo de tiempo: During the treatment procedure
|
Middle meningeal arteries with dangerous anastomoses observed on imaging |
During the treatment procedure
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: Manisha Koneru, MD, The Cooper Health System
- Investigador principal: Jane Khalife, MD, The Cooper Health System
- Silla de estudio: Ajith J Thomas, MD, The Cooper Health System
Publicaciones y enlaces útiles
Publicaciones Generales
- Khalife J, Koneru M, Thomas AJ. Inflammation as a Key Driver for Chronic Subdural Hematomas. Stroke. 2026 Jul;57(7):1908-1919. doi: 10.1161/STROKEAHA.126.055340. Epub 2026 May 27.
- Khalife J, Koneru M, Tonetti DA, Shaikh HA, Jovin TG, Patel PD, Thomas AJ. Intra-arterial Selective Bevacizumab Administration in the Middle Meningeal Artery for Chronic Subdural Hematoma: An Early Experience in 12 Hemispheres. Stroke Vasc Interv Neurol. 2024 Jul 22;4(5):e001409. doi: 10.1161/SVIN.124.001409. eCollection 2024 Sep.
- Khalife J, Tonetti DA, Shaikh H, Jovin T, Patel P, Thomas A. Intraarterial Bevacizumab Administration Through the Middle Meningeal Artery for Chronic Subdural Hematoma. Stroke Vasc Interv Neurol. 2023 Feb 25;3(4):e000722. doi: 10.1161/SVIN.122.000722. eCollection 2023 Jul.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Heridas y Lesiones
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Hemorragia
- Trauma craneoencefálico
- Trauma, Sistema Nervioso
- Hemorragias intracraneales
- Hemorragia Intracraneal Traumática
- Condiciones Patológicas, Signos y Síntomas
- Hematoma Subdural
- Hematoma
- Hematoma Subdural Crónico
- Aminoácidos, péptidos y proteínas
- Proteínas
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Bevacizumab
Otros números de identificación del estudio
- 23-154
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .